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Mice deficient for Spa-1 encoding Rap GTPase-activating protein
develop myeloproliferative disorder (MPD) of late onset with fre-
quent blast crises. The mechanisms for MPD development as well
as the reasons for long latency, however, remain elusive. We dem-
onstrate here that preleukemic, disease-free Spa-1) ⁄ ) mice show
reduced steady-state hematopoiesis and attenuated resistance to
whole body c-ray irradiation, which are attributable to the
sustained p53 response in hematopoietic progenitor cells (HPCs).
Preleukemic Spa-1) ⁄ ) HPCs show c-Myc overexpression with
increased p19Arf as well as enhanced cH2AX expression with acti-
vation of Atm ⁄Chk pathway. We also show that deregulated Rap
signaling in the absence of Spa-1 enhances post-transcriptional c-
Myc stability and induces DNA damage in a p38MAPK-dependent
manner, leading to p53 activation. Genetic studies indicate
that the introduction of p53+ ⁄ ) and p53) ⁄ ) mutations in Spa-1) ⁄ )
mice results in the acceleration of typical MPD and rapid develop-
ment of blastic leukemia, respectively. These results suggest
that increased c-Myc expression and DNA damage in HPCs pre-
cede MPD development in Spa-1) ⁄ ) mice, and the resulting
p53 response functions as a barrier for the onset of MPD and
blast crises progression. (Cancer Sci 2011; 102: 784–791)
C hronic myelogenous leukemia (CML) is a disorder ofhematopoietic stem cells (HSCs). It is initiated as chronic
myeloproliferative disease (MPD) but eventually progresses to
acute leukemia called blast crisis (BC).(1) Initiation of human
CML is considered to involve comprehensive interaction of
Bcr-Abl with host factors intrinsic to HSCs, whereas BC is asso-
ciated with additional genomic changes of hematopoietic
progenitor cells (HPCs).(2) Although Bcr-Abl per se is suggested
to be responsible for the genomic instability and disease
progression, underlying mechanisms remain elusive.(3) MPD
resembling human CML has been reported in several mouse
models, including Nf1) ⁄ ) mice and transgenic mice expressing
oncogenic K-ras.(4–6) MPD in these mice, however, was not
transferable to normal mice and rarely progressed to BC.(5,7)
We previously reported that deregulated activation of Rap, a
Ras-family GTPase, in HPCs caused a spectrum of hematologic
malignancy.(8–11) Typically, mice deficient for Spa-1 encoding a
principal Rap-specific GTPase-activating protein showed dereg-
ulated Rap activation in HPCs and developed chronic MPD
with progression to BC.(8) We also reported that Rap was acti-
vated in human CML and CML-BC cells,(12) and that mouse
Spa-1) ⁄ ) HPCs expressing Bcr-Abl showed aggravated MPD
phenotype with accelerated BC progression.(13) On the other
hand, recent results indicate that endogenous Rap signaling
plays crucial roles in normal lymphohematopoiesis. Thus, con-
ditional abrogation of Rap activation in T- and B-lineage cells
caused developmental arrest of thymic pre-T cells and defective
bone marrow (BM) pre-B cell development, respectively.(14,15)
A most recent report indicated that the deficiency of Rap guan-
ine nucleotide exchange factor 2 resulted in the complete defect
of embryonic hematopoiesis.(16)
One of the features of MPD in Spa-1) ⁄ ) mice was a quite
long latency for the disease onset, suggesting the involvement of
secondary genetic hits.(8) In the present study, we investigated
the features of Spa-1) ⁄ ) HPCs prior to overt hematologic disor-
der. We demonstrate that preleukemic Spa-1) ⁄ ) HPCs show
marked increase of c-Myc and DNA damage causing sustained
p53 activation, which significantly delays the disease onset.
Materials and Methods
Mice. Spa-1) ⁄ ) mice were backcrossed to C57BL ⁄6 (B6)
mice for more than 15 generations. B6 and p53) ⁄ ) mice with a
B6 background were purchased from SLC (Shizuoka, Japan)
and Taconic Farm (Hudson, NY, USA), respectively. All mice
were maintained under pathogen-free conditions at the Institute
of Laboratory Animals, Kyoto University Graduate School of
Medicine. All animal procedures were performed according to
the guidelines for animal experiments of Kyoto University.
Hematological assays. Peripheral blood leukocytes were
monitored with the use of an automated cell counter (Nihon
Kohden, Tokyo, Japan). BM cells were cultured in methylcellu-
lose medium in the presence of stem cell factor (SCF;
50 ng ⁄mL; PeproTech Inc., Rocky Hill, NJ, USA) and interleu-
kin-3 (IL-3, 10 ng ⁄mL) for 7 days. For spectral karyotyping
(Sky) analysis, cells were treated with corcemid (Karyo Max;
Life Technologies, Carlsbad, CA, USA).
Flow cytometry and cell separation. BM cells were five-color
stained with propidium iodide (PI), a cocktail of Lin-marker
antibodies (BD Bioscience, Franklin Lakes, NJ, USA) with
additional anti-IL-7R, anti-Sca-1, anti-c-Kit, anti-CD16 ⁄32 and
anti-CD34 antibodies. Common myeloid progenitors, megakaryo-
erythroid progenitors, and granulocyte-macrophage progenitors
were defined as CD16 ⁄32low CD34+, CD16 ⁄32low CD34), and
CD16 ⁄32high CD34+ populations, respectively, in a Lin) c-Kit+
Sca-1) IL7-R) gate. For BrdU ⁄7-AAD staining, the cells were
first three-color stained with anti-c-Kit, anti-Sca-1 and anti-Lin
marker antibodies, fixed and permealized, treated with DNase I,
and then incubated with anti-BrdU antibody and 7-AAD. Lin)
HPCs were isolated using FACSAria II (BD Biosciences) or
AutoMax (Miltenyl Biotec, Bergisch Gladbach, Germany).
Immunoblotting and immunostaining. Cells were lysed with
RIPA buffer (150 mM NaCl, 25 mM Tris–HCl [pH 7.6], 1%
NP-40, 1% sodium deoxycholate, 0.1% SDS, protease and
phosphatase inhibitors) and immunoblotted. Antibodies used
were as follows; anti-Spa-1, anti-p53, anti-phosphorylated
(S15) p53, anti-phosphorylated (S1981) Atm, anti-c-Myc,
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anti-Foxo3a, (Cell Signaling Technology, Beverly, MA, USA);
anti-p21Cip1, anti-p16Ink4a, anti-Pten, anti-Actin, anti-Atm,
anti-Chk2, anti-C3G, anti-Rap1 (Santa Cruz Biotechnology,
Santa Cruz, CA, USA); anti-Trp53inp1, anti-phosphorylated
(T68) Chk2, anti-phosphorylated (S62, T58) c-Myc (Abcam,
Cambridge, UK); anti-p19Arf (Calbiochem, Billercia, MA,
USA); anti-Mdm2 (R&D Systems, Mineapolis MN, USA); anti-
Trp53BP1(Bethyl Laboratories, Montogomery, TX, USA); anti-
cH2AX (S129) (Upstate); anti-Brm (BD Transduction
Laboratories, Franklin Lakes, NJ, USA). Rap-GTP was detected
by pull-down assay. For immunostaining, cells were fixed with
methanol, permealized, blocked, and incubated with anti-
cH2AX antibody (Upstate Co., Billercia, MA, USA) and DAPI.
The images were visualized using a ZEISS Axiovert200M
microscope equipped with an Axiocam MRm camera (Carl
Zeiss MicroImaging, Gottingen, Germany).
Quantitative PCR. Total RNA was extracted from the sorted
lin) BM cells with a NucleoSpin RNA kit (Macherey-Nagel,
Dueren, Germany) followed by cDNA synthesis with Super-
Script III (Invitrogen, Carlsbad, CA, USA). Real-time PCR was
performed with a LightCycler SYBR Green I marker kit on a
LightCycler instrument (Roche, Basel, Switzerland). The primer
pairs were as follows—Trp53: sense, 5¢-GCCCATGCTACAG-
AGGAGTC-3¢; anti-sense, 5¢-AGACTGGCCCTTCTTGGTCT-
3¢; c-Myc: sense, 5¢-CGAAACTCTGGTGCATAAACTG-3¢;
anti-sense, 5¢-GAACCGTTCTCCTTAGCTCTCA-3¢; Arf: sense,
5¢-CGACGGGCATAGCTTCAG-3¢; anti-sense, 5¢-GCTCTGC-
TCTTGGGATTGG-3¢.
Retrovirus production and infection. PLAT-E cells were
transfected with a pMCs-ires-EGFP retroviral vector containing
farnesylated C3G (C3G-F) or Rap1A17 mutant cDNA and pSI-
REN-Retro Q vector (Clontech Lab, Mountain View, CA, USA)
containing Spa-1 shRNA, and the culture supernatants were har-





Bone marrow chimeras. BM cells (2 · 107 cells ⁄head) were
injected intravenously into mice lethally irradiated with 13 Gy
c-ray (6.5 Gy twice with a 4-h interval).
Statistical analysis. Statistical analysis was performed using
the Log-rank (Mantel–Cox) test for Kaplan–Meier analysis and
two-tailed Student’s t-test for other experiments.
Results
Reduced steady-state hematopoiesis in preleukemic Spa-1) ⁄ )
mice. We first investigated the hematopoietic activity of young,
disease-free Spa-1) ⁄ ) mice. Rather unexpectedly, 8-week-old
Spa-1) ⁄ ) mice were leukopenic compared with age-matched lit-
termate control (LMC) mice (13, 340 ± 356 ⁄lL in LMC,
n = 43 versus 8, 651 ± 262 ⁄lL in Spa-1) ⁄ ) mice, n = 28;
P < 0.001). Total BM nucleated cell numbers were also dimin-
ished significantly (Fig. 1a). Flow cytometric analysis indicated
that the numbers of Lin) c-Kit+ Sca-1+ (LKS) as well as
committed progenitor (Lin) c-Kit+ Sca-1), LKS)) cells for all
myeloid cell lineages were diminished (Fig. 1a). To examine
steady-state cycling status of HPCs in vivo, we injected BrdU
4 h before sacrifice. Both LKS and LKS) populations of
(a)
(b)
Fig. 1. Preleukemic Spa-1) ⁄ ) mice show reduced steady-state hematopoiesis. (a) Bone marrow (BM) cells from disease-free Spa-1) ⁄ ) and
littermate control (LMC) mice were multicolor analyzed, and total nucleated cell numbers as well as those of Lin) c-kit+ Sca-1+ (LKS), Lin) c-kit+
Sca-1) (LKS)), megakaryo-erythroid progenitors (MEP), common myeloid progenitors (CMP) and granulocyte-macrophage progenitors (GMP)
were determined. (b) Spa-1) ⁄ ) and LMC mice were injected with BrdU, and 4 h later the BM cells were multicolor analyzed with Lin cocktail,
anti-c-Kit, anti-Sca-1, anti-BrdU and 7-AAD. Representative staining profiles in LKS and LKS)gates as well as the means and SE of cell cycle stages
are shown (n = 6 for each group). A portion of LKS) population was in the second round of cell cycle (triangles).
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Spa-1) ⁄ ) mice revealed significantly higher proportions of the
cells at G0 ⁄G1 phase than those of LMC mice with few apopto-
tic sub-G1 cells (Fig. 1b).
Preleukemic Spa-1) ⁄ ) mice show attenuated resistance to total
body c-ray irradiation. The findings prompted us to investigate
the hematopoietic activity of Spa-1) ⁄ ) mice in response to
extrinsic stress. Young Spa-1) ⁄ ) mice showed remarkably
increased mortality after otherwise sublethal total body irradia-
tion (TBI) with 7 or 8 Gy c-ray (Fig. 2a). Although LCM BM
cells began to regenerate on day 7 with nearly complete recov-
ery by day 13 after 7 Gy TBI, no evidence for the regeneration
was detected in Spa-1) ⁄ ) BM until moribund (Fig. 2b). No path-
ological evidence was found in other tissues including brain and
intestine in both Spa-1) ⁄ ) and LMC mice, suggesting that the
enhanced mortality was attributable to BM failure. In agreement
with the findings, SCF ⁄ IL-3-induced colony-forming unit (CFU)
numbers in LMC BM recovered close to the normal level by
14 days, whereas those in Spa-1) ⁄ ) BM were progressively
reduced until moribund (Fig. 2c). Spa-1) ⁄ ) HPCs also showed
significantly enhanced susceptibility to c-ray irradiation in vitro
than LCM HPCs with respect to the SCF ⁄ IL-3-induced CFU
activity (Fig. 2d).
Enhanced radio-susceptibility of Spa-1) ⁄ ) mice is attributable
to sustained p53 activation in HPCs. To confirm that the attenu-
ated radio-resistance of Spa-1) ⁄ ) mice was HPC-autonomous,
we generated BM chimeric mice. As anticipated, Spa-1) ⁄ ) mice
reconstituted with Spa-1) ⁄ ) BM all died after 7 Gy TBI,
whereas LCM mice reconstituted with LCM BM all survived.
On the other hand, LCM mice reconstituted with Spa-1) ⁄ ) BM
all died following 7 Gy TBI similar to Spa-1) ⁄ ) mice, while five
out of nine Spa-1) ⁄ ) mice reconstituted with LCM BM survived
(Fig. 3a). The results indicate that the enhanced radio-suscepti-
bility of Spa-1) ⁄ ) mice is primarily HPC-autonomous, although




Fig. 2. Spa-1) ⁄ ) mice show attenuated resistance to total body c-ray irradiation. (a,b) Preleukemic Spa-1) ⁄ ) and littermate control (LMC) mice
received total body irradiation (TBI) (7Gy or 8Gy), and their survival was monitored for 3 months. BM histology of femoral bones was examined
at various days after 7Gy TBI. H&E · 100. (c) Spa-1) ⁄ ) and LMC mice received TBI (7Gy), and varying weeks later stem cell factor ⁄ interleukin-3
(SCF ⁄ IL-3)-induced colony-forming unit (CFU) numbers in the BM cells were determined. The means and SE of three mice are shown. (d) BM cells
from Spa-1) ⁄ ) and LMC mice were irradiated in vitro with varying doses of c-ray and the numbers of SCF ⁄ IL-3-induced CFUs were determined.
The means and SE of triplicate culture are shown. BMC, bone marrow cells.
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is also suggested. Considering the crucial role of p53 in
radiation-induced myelosuppression, we investigated the
expression of p53 in HPCs. Freshly isolated Lin) BM cells from
unirradiated Spa-1) ⁄ ) mice expressed remarkably increased p53
with reduced Mdm2 compared with those of LCM and accord-
ingly increased expression of potential p53-target proteins such
as p21, Pten, and Trp53inp1 (Fig. 3b). Expression of p16INK4a
was largely comparable (Fig. 3b). To directly examine the
contribution of p53, we generated Spa-1) ⁄ ) mice with p53+ ⁄ ) or
p53) ⁄ ) backgrounds. Whereas Spa-1) ⁄ )p53+ ⁄ ) mice died
comparably with Spa-1) ⁄ ) mice after 7 Gy TBI, all Spa-1) ⁄ )
p53) ⁄ ) mice survived (Fig. 3c). These results suggested that the
attenuated radio-resistance of preleukemic Spa-1) ⁄ ) mice was
attributable to the sustained p53 activation in HPCs.
Increased DNA damage and c-Myc expression underlie p53
activation in Spa-1) ⁄ ) HPCs. Freshly isolated Lin) BM cells
(HPCs) from preleukemic Spa-1) ⁄ ) mice showed significant
expression of cH2AX along with the increase of Brm that
(a) (b)
(c)
Fig. 3. Attenuated radio-resistance of Spa-1) ⁄ )
mice is hematopoietic progenitor cells (HPC)-
autonomous and attributable to p53 response. (a)
BM chimeric mice of indicated combinations
received 7Gy total body irradiation (TBI), and the
survival was monitored for 3 months. (b) Lin) BM
cells from unirradiated Spa-1) ⁄ ) and littermate
control (LMC) mice were immunoblotted with
indicated antibodies. (c) Indicated numbers of LMC,
p53) ⁄ ), Spa-1) ⁄ ), Spa-1) ⁄ )p53+ ⁄ ) and Spa-
1) ⁄ )p53) ⁄ ) mice received TBI (7Gy), and the survival
was monitored for a month.
(a) (b) (c)
(d)
Fig. 4. Preleukemic Spa-1) ⁄ ) hematopoietic progenitor cells (HPCs) show increased c-Myc activation and DNA damage response. (a–c) Lin) BM
cells isolated from littermate control (LMC) and Spa-1) ⁄ ) mice were immunoblotted with indicated antibodies. (d) Transcripts of indicated genes
were assessed by quantitative RT-PCR in Lin) BM cells from LMC and Spa-1) ⁄ ) mice. The values were normalized to those of cyclophilin, and
relative transcripts in Spa-1) ⁄ ) to LMC HPCs are shown. NS, not significant.
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promotes cH2AX induction(17) and Trp53BP1 that plays a cru-
cial role in activating DNA damage response (Fig. 4a,b).(18)
Moreover, Spa-1) ⁄ ) HPCs exhibited enhanced expression and
phosphorylation of Atm, phosphorylation of its substrate
Chk2, and prominent N-terminal phosphorylation of p53 at
S15 (Fig. 4b), suggesting the sustained activation of DNA
damage response. In addition, Spa-1) ⁄ )HPCs also showed
remarkably increased c-Myc and reduced Fbw7 with concomi-
tantly enhanced expression of Foxo3a and p19ARF (Fig. 4c).
The transcripts of c-myc, however, were unchanged, although
Arf transcripts were increased (Fig. 4d). The transcripts of p53
were not changed either, whereas Pten transcripts were
increased (Fig. 4d). These results suggest that deregulated
c-Myc expression and increased DNA damage underlie the
sustained increase and activation of p53 in preleukemic
Spa-1) ⁄ ) HPCs.
Basal Rap signaling regulates c-Myc expression and DNA
damage in a p38MAPK dependent manner. We next addressed
whether or not deregulated Rap signaling in Spa-1-deficiency
was involved in the sustained p53 activation. Toward this end,
we generated NIH3T3 cells with varying levels of endogenous
Rap-GTP; namely, NIH3T3 expressing dominant negative
Rap1A17, empty vector (Vect), constitutive active Rap-GEF
C3G (C3G-F), and Spa-1 shRNA (shSpa-1) in addition to C3G-
F, with increasing basal Rap-GTP levels in this order (Fig. 5a).
It was confirmed that the expression levels of p53 were
increased in proportion to the increasing levels of basal Rap-
GTP, while the transcripts were unchanged (Fig. 5a). The effect
was paralleled with the increase of c-Myc expression, with mini-
mal change in c-myc transcripts (Fig. 5a). It was noted that the
increase of c-Myc was associated with the enhanced S62 and
diminished T58 phosphorylation, particularly in the cells show-
ing the highest Rap activation (Fig. 5a). Moreover, the cells
with the highest Rap–GTP also exhibited increased expression
of cH2AX and Trp53BP1 with characteristic chromatin conden-
sation (Fig. 5b), indicative of increased DNA damage. These
cells also showed significantly increased Nox2 expression
(Fig. 5b).
Spa-1) ⁄ ) HPCs showed enhanced p38MAPK, but not ERK,
activation, and, in agreement, NIH3T3 with deregulated Rap
activation also showed enhanced p38MAPK activation
(Fig. S1). We then investigated the effect of a p38MAPK inhib-
itor (SB202190) on c-Myc expression and DNA damage in
NIH3T3 cells with deregulated Rap activation. Abundant
c-Myc expression in NIH3T3 ⁄C3G-F:shSpa-1 cells was sup-
pressed by the treatment with SB202190 in a dose-dependent
manner, and the effect was associated with the abrogation of
S62 and the restoration of T58 phosphorylation of c-Myc as
well as increase Fbw7 expression (Fig. 5c). Expression of
Nox2, cH2AX, and Trp53BP1 was also suppressed by
SB202190 treatment in parallel, and consequently p53 expres-
sion was diminished significantly (Fig. 5c). The stability of
c-Myc protein in the presence of cycloheximide was signifi-
cantly increased in NIH3T3 ⁄C3G-F:shSpa-1 cells compared
with NIH3T3 ⁄Vect cells (Fig. 5d), suggesting the increased
c-Myc expression was attributable to the enhanced protein
stability at least in part. The results suggest that deregulated
Rap signaling in Spa-1-deficiency induces the increase of
c-Myc expression and DNA damage via p38MAPK pathway,
leading to sustained p53 activation.
Sustained p53 response functions as a barrier for MPD and BC
in Spa-1) ⁄ ) mice. MPD in Spa-1) ⁄ ) mice was successively
transferable into Rag2) ⁄ ) mice and progressed to blastic leuke-
mia during in vivo passage (Fig. S2), confirming the intrinsic
propensity for BC progression. We then finally validated the role
of sustained p53 response in preleukemic Spa-1) ⁄ ) HPCs. In the
current cohort, 16 out of 17 Spa-1) ⁄ ) mice developed MPD only
after 50 weeks (the mean survival time: 84 weeks), while
p53) ⁄ ) mice died of either sarcoma (62%) or T-ALL (24%)
by 35 weeks of age with no case of MPD (the mean survival
time: 26 weeks, n = 21) (Fig. 6a). Spa-1) ⁄ )p53) ⁄ ) mice all died
significantly earlier than p53) ⁄ ) mice (the mean survival time:
17 weeks, n = 25, P < 0.0001) with increased proportion of
T-ALL (48%) (Fig. 6a). Notably, 28% of Spa-1) ⁄ )p53) ⁄ ) mice
developed non T-lineage blastic leukemia, apparently bypassing
the MPD phase, with gross chromosomal translocations
(Fig. 6b), whereas Spa-1+ ⁄ +p53) ⁄ ) mice never developed non
T-lineage leukemia (Fig. 6a). Furthermore, although p53+ ⁄ )
mice developed no hematologic disorder, eight out of 31 Spa-
1) ⁄ )p53+ ⁄ ) mice died within a year, and five of them were
confirmed by autopsy to show typical MPD with severe anemia,
extramedullary hematopoiesis, and marked increase of mature
myeloid cells (Fig. 6c). The results suggest that sustained p53
response in HPCs plays a pivotal role as a barrier for the
development of MPD and BC progression in Spa-1) ⁄ )mice,
significantly delaying the disease onset.
Discussion
Rap signaling plays an important role in normal lymphohemato-
poiesis; deregulated Rap activation in HPCs may cause MPD
and leukemia, whereas defective Rap activation results in
impaired lymphohematopoiesis.(10,11) In current study, we inves-
tigated the underlying mechanisms of late-onset MPD in Spa-
1) ⁄ ) mice, which showed deregulated Rap activation in the
HPCs.(8) Prior to overt MPD development, Spa-1) ⁄ ) mice
showed rather reduced steady-state hematopoiesis and attenu-
ated radio-resistance, which were attributable to the sustained
p53 activation in HPCs. The reduced hematopoiesis was attrib-
utable primarily to the diminished cell cycle progression of
HPCs with little evidence of cell death. In either case, the results
strongly suggest that the HPCs of preleukemic Spa-1) ⁄ ) mice
are under the intrinsic ‘‘stress’’ that provokes p53 response. We
demonstrated that Spa-1) ⁄ ) HPCs showed increased expression
of cH2AX and activation of Trp53BP1 ⁄Atm ⁄Chk2 pathway,
suggesting that the increased DNA damage may in part contrib-
ute to the p53 activation. In addition, Spa-1) ⁄ ) HPCs showed
c-Myc overexpression along with a prominent increase of
p19Arf, which antagonizes Mdm2 activity and suppresses the
degradation of p53 protein.(19–21) It was noticed that Mdm2
expression per se tended to be reduced in Spa-1) ⁄ ) HPCs, and it
remained to be investigated whether or not the effect was also
attributable to the increased p19Arf. It is shown that deregulated
c-Myc expression may induce DNA damage directly via aber-
rant DNA replication and ⁄ or indirectly by inducing reactive
oxygen species generation.(22,23) Current results indicate that
Spa-1) ⁄ ) HPCs show increased expression of Nox2 capable of
generating reactive oxygen species. In either case, present
results suggest that deregulated c-Myc expression and increased
DNA damage underlie the sustained p53 response in preleuke-
mic Spa-1) ⁄ ) HPCs.
With the use of NIH3T3 cells with varying levels of basal
Rap activation, we confirmed that deregulated Rap activation
caused marked activation of p53 in association with the
increase of c-Myc and cH2AX expression. The increase of
c-Myc was not related to the increase of c-myc transcripts,
suggesting the post-transcriptional effect. Stability of c-Myc
protein is crucially regulated by phosphorylation at two
N-terminal residues, S62 and T58; thus, S62 phosphorylation
confers stability, whereas its dephosphorylation followed by
T58 phosphorylation targets c-Myc to the ubiquitin-dependent
degradation.(21,24,25) Overexpressed c-Myc in the cells with
deregulated Rap activation showed strong S62 with minimal
T58 phosphorylation. MAPKs such as ERK and JNK2 are
reported to function as a S62 kinase of c-Myc.(21) The cur-
rent study, however, indicated that a p38MAPK inhibitor
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significantly suppressed the expression of c-Myc in these cells,
and the effect was associated with the reduced S62 and
increased T58 phosphorylation and increased Fbw7. In agree-
ment, c-Myc protein in the cells with deregulated Rap activa-
tion showed increased half life at steady state. It is thus
suggested that Rap signaling regulates c-Myc protein stability
via p38MAPK pathway, although exact mechanisms for the
modification of c-Myc phosphorylation status by p38MAPK
remain to be verified. The results are consistent with the
increased p38MAPK activation in Spa-1) ⁄ ) HPCs.(26) Myc
proteins play an essential role in normal hematopoiesis,(27,28)
and a recent report indicates that c-Myc abundance during nor-
mal HSC differentiation and proliferation is almost exclusively
regulated by post-translational regulation.(29) Also, we reported
(a) (b)
(c) (d)
Fig. 5. Deregulated Rap signaling induces enhanced c-Myc activation and DNA damage response. (a) NIH3T3 cells expressing Rap1A17, empty
vector, C3G-F, or C3G-F + shSpa-1 were immunoblotted with indicated antibodies. Because Rap-GTP levels varied markedly, pull-down assay was
done separately in two sets with different conditions. Transcripts of c-myc and p53 were assessed with quantitative RT-PCR. (b) NIH3T3 ⁄Vect and
NIH3T3 ⁄ C3G-F:shSpa-1 cells were immunoblotted with indicated antibodies and immunostained with anti-cH2AX (red) and DAPI (blue). (c)
NIH3T3 ⁄ C3G-F:shSpa-1 cells were cultured in the presence of varying concentrations of SB202190 for 24 h and immunoblotted with indicated
antibodies. (d) NIH3T3 ⁄Vect and NIH3T3 ⁄ C3G-F:shSpa-1 cells were cultured in the presence of cycloheximide (CHX; 100 lg ⁄mL). At various time
points later, the cells were recovered and immunoblotted with indicated antibodies (upper). Relative signal intensities of c-Myc normalized to
those of corresponding Gapdh are plotted (lower). NS, not significant.
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that conditional transgenic mice expressing dominant negative
Rap1A17 showed markedly diminished c-Myc expression in B
progenitor cells and defective B-cell development.(15) Thus, it
may be an intriguing possibility that the crucial role of Rap
signaling in normal lymphohematopoiesis is mediated in part
by the regulation of c-Myc expression levels in HPCs.
Constitutive c-Myc overexpression is detected in a wide spec-
trum of human cancers and leukemia by genomic changes such
as mutations, gene duplication and chromosomal translocations,
and its role in leukemia genesis has been explored by a number
of animal models.(20) Current results, however, suggest that
deregulated Rap activation induces c-Myc overexpression in
HPCs primarily via post-translational mechanisms, leading to
the sustained p53 response. We have demonstrated that the p53
activation in Spa-1) ⁄ ) HPCs functions as a significant barrier for
the development of MPD and BC. Although p53 deficiency
alone rarely resulted in hematological malignancy except for
thymic T-cell leukemia, a significant proportion of Spa-
1) ⁄ )p53+ ⁄ ) mice developed characteristic MPD much earlier
than Spa-1) ⁄ ) mice, and one-thirds of Spa-1) ⁄ ) p53) ⁄ ) mice
rapidly developed blastic leukemia of non-T-cell lineages,
apparently bypassing the MPD phase. The blastic leukemia cells
in Spa-1) ⁄ ) p53) ⁄ ) mice expressed abundant c-Myc with gross
chromosomal translocations, although the direct role of c-Myc in
MPD and BC remains to be formerly proved. Human CML cells




Fig. 6. The sustained p53 response functions as a barrier for myeloproliferative disorder (MPD) and blast crisis in Spa-1) ⁄ ) mice. (a) Kaplan–Meier
analysis of the survival of indicated numbers of Spa-1) ⁄ ), Spa-1) ⁄ )p53+ ⁄ ), Spa-1) ⁄ )p53) ⁄ ), p53) ⁄ ) and p53+ ⁄ )mice (left). Although not shown, 17 out
of 18 Spa-1) ⁄ ) mice died in the second year of life. Causes of death by the autopsy of moribund mice are summarized (right). (b,c) Peripheral blood
cells from the representative diseased Spa-1) ⁄ )p53) ⁄ ) and Spa-1) ⁄ )p53+ ⁄ ) mice were cytospun and stained with Giemsa solution. Arrows indicate
blast cells. Themean values of white blood cells (WBC), red blood cells (RBC) and spleenweights in disease-free Spa-1) ⁄ )micewere 8.7 (·10)3 ⁄ lL), 1010
(·10)4 ⁄ lL) and 150 (mg), respectively. Sky analysis of the typical blastic leukemia cells in Spa-1) ⁄ )p53) ⁄ )mice is shown.
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instability, and the majority of BC cells show the anomalies in
the genes related to DNA damage response, such as p53, ARF,
and Rb.(1,30) On the other hand, we previously reported that
human CML and BC cells showed constitutive Rap activa-
tion,(12) and also Spa-1-deficiency strongly accelerated the BC
progression of Bcr-Abl-induced CML in a mouse model.(13)
Thus, current results suggest that Rap signaling may link Bcr-
Abl to the sustained DNA damage in HSC ⁄HPCs, and may pro-
vide a strategic clue to control human CML and its inevitable
progression to BC.
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